Equibles does not estimate personal net worth.
Get an email with a short summary when Viking Therapeutics, Inc. publishes a filing, an earnings call transcript or a press release.
Get VKTX alertsGreg Zante is recorded as CFO at Viking Therapeutics, Inc. (VKTX). The newest filing on record that lists Greg Zante as CFO at Viking Therapeutics, Inc. (VKTX) is dated April 1, 2026. The proxy statement of Viking Therapeutics, Inc. reports total compensation of $5,135,872 for Greg Zante in fiscal 2025, including a base salary of $521,000. Disclosed compensation is on record for 5 fiscal years. Greg Zante has spoken on 15 earnings calls across 1 company, most recently for Viking Therapeutics, Inc. on July 29, 2026. Viking Therapeutics, Inc. is classified in the Biotechnology industry within the Healthcare sector. Other leadership on record at Viking Therapeutics, Inc. includes Brian Lian (CEO and Board Member), Marianne Mancini (COO), Brian Lian, Ph.D. (Board Member) and 5 others.
“In conjunction with my comments, I'd like to recommend that participants refer a Viking's Form 10-Q filing with the Securities and Exchange Commission, which we expect to file shortly.”
“In conjunction with my comments, I'd like to recommend that participants refer to Vikings Form 10-Q filing with the Securities and Exchange Commission, which we expect to file shortly.”
“In conjunction with my comments, I'd like to recommend that participants refer to Viking's Form 10-K filing with the Securities and Exchange Commission, which we expect to file shortly.”
“In conjunction with my comments, I'd like to recommend that participants refer to Viking's Form 10-Q filing with the Securities and Exchange Commission, which we expect to file later today.”
“In conjunction with my comments, I'd like to recommend that participants refer to Viking's Form 10-Q filing with the Securities and Exchange Commission, which we expect to file later today.”
Start not stated–present
Last confirmed April 1, 2026
Source not stated
Biotechnology · Healthcare
CFO
Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.
| Fiscal year | Company | Role | Salary | Total |
|---|---|---|---|---|
| 2025 | Viking Therapeutics, Inc. (VKTX) | Chief Financial Officer | $521,000 | $5,135,872 |
| 2024 | Viking Therapeutics, Inc. (VKTX) | Chief Financial Officer | $475,000 | $4,681,394 |
| 2023 | Viking Therapeutics, Inc. (VKTX) | Chief Financial Officer | $455,000 | $3,495,957 |
| 2022 | Viking Therapeutics, Inc. (VKTX) | Chief Financial Officer | $425,000 | $1,710,661 |
| 2021 | Viking Therapeutics, Inc. (VKTX) | Chief Financial Officer | $400,000 | $1,345,330 |
